Related Experiment Video
Updated: Jun 13, 2026
09:32
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
Understanding therapeutic equivalence in epilepsy
Raman Sankar1, Tracy A Glauser
1David Geffen School of Medicine at UCLA, Mattel Children's Hospital, Los Angeles, CA 90095-1752, USA. rsankar@ucla.edu
CNS Spectrums
|April 24, 2010
Summary
Generic drug substitution in epilepsy patients is complex. Switching antiepileptic drugs (AEDs) can alter therapeutic efficacy and requires physician approval due to potential risks.
Area of Science:
- Neurology
- Pharmacology
- Clinical Pharmacy
Background:
- Generic drug substitution for antiepileptic drugs (AEDs) is controversial.
- Regulatory agencies mandate pharmacokinetic bioequivalence, but therapeutic efficacy may differ.
- Epilepsy management requires precise dosing and consistent drug exposure.
Purpose of the Study:
- To examine the complexities and implications of generic drug substitution in epilepsy patients.
- To highlight the potential risks associated with switching AED formulations.
- To emphasize the importance of physician oversight and patient consultation.
Main Methods:
- Review of existing literature on AED substitution and therapeutic equivalence.
- Analysis of pharmacokinetic and pharmacodynamic considerations in epilepsy.
- Discussion of clinical implications for seizure control and patient safety.
Main Results:
- Despite bioequivalence, formulation changes can lead to altered plasma concentrations and therapeutic outcomes.
- The unique characteristics of epilepsy (paroxysmal nature, narrow therapeutic index) heighten risks.
- Individualized therapy and consistent drug exposure are critical for seizure control.
Conclusions:
- Substitution of AED formulations in epilepsy patients is not recommended without explicit physician knowledge and approval.
- Informed patient consent, detailing risks and benefits, is essential before any substitution.
- Maintaining therapeutic drug levels and seizure control should be prioritized over generic substitution.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...